Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Prostate Cancer

  Free Subscription

Articles published in Prog Urol

Retrieve available abstracts of 71 articles:
HTML format

Single Articles

    January 2021
  1. BERTOLO R, Vittori M, Cipriani C, Maiorino F, et al
    Diagnostic pathway of the biopsy-naive patient suspected for prostate cancer: Real-life scenario when multiparametric Magnetic Resonance Imaging is not centralized.
    Prog Urol. 2021 Jan 8. pii: S1166-7087(20)30747.
    PubMed     Abstract available

  2. CULTY T, Goujon A, Defortescu G, Bessede T, et al
    [Localized Prostate cancer in candidates for renal transplantation and recipients of a kidney transplant: The French Guidelines from CTAFU].
    Prog Urol. 2021;31:4-17.
    PubMed     Abstract available

    November 2020
  3. VESVAL Q, Fiard G, Villers A, Norris JM, et al
    Should we perform systematic biopsies in case of suspicious MRI for prostate cancer in 2020? A review of literature.
    Prog Urol. 2020 Nov 11. pii: S1166-7087(20)30603.
    PubMed     Abstract available

  4. ROZET F, Mongiat-Artus P, Hennequin C, Beauval JB, et al
    [French ccAFU guidelines - update 2020-2022: prostate cancer].
    Prog Urol. 2020;30.
    PubMed     Abstract available

    October 2020
  5. KAULANJAN K, Thenault R, Leroy V, Khene Z, et al
    [Management of hormone deprivation therapies in prostate cancer: Role of the nurse].
    Prog Urol. 2020 Oct 24. pii: S1166-7087(20)30600.
    PubMed     Abstract available

    September 2020
  6. GOUJON A, Legrand G, Verine J, Hennequin C, et al
    [Active surveillance of prostate cancer: treatement-free survival according to restricted or expanded eligibility criteria].
    Prog Urol. 2020 Sep 12. pii: S1166-7087(20)30109.
    PubMed     Abstract available

  7. MJAESS G, Karam A, Aoun F, Albisinni S, et al
    COVID-19 and the male susceptibility: the role of ACE2, TMPRSS2 and the androgen receptor.
    Prog Urol. 2020;30:484-487.
    PubMed     Abstract available

    July 2020
  8. GAS J, Dominique I, Mathieu R, Poinas G, et al
    [Radical prostatectomy for prostate cancer, perioperative management by French urologists in 2018].
    Prog Urol. 2020 Jul 6. pii: S1166-7087(20)30228.
    PubMed     Abstract available

    June 2020
  9. PERCOT M, Robert G, Bladou F, Ferriere JM, et al
    Active surveillance in prostate cancer is possible for Afro-Caribbean population: Comparison of oncological outcomes with a Caucasian cohort.
    Prog Urol. 2020 Jun 24. pii: S1166-7087(20)30185.
    PubMed     Abstract available

  10. ROZET F, Hennequin C, Beuzeboc P, Mathieu R, et al
    [French CCAFU guidelines on prostate cancer: hormone-sensitive metastatic prostate cancer-update 2020].
    Prog Urol. 2020 Jun 6. pii: S1166-7087(20)30139.
    PubMed     Abstract available

    May 2020
  11. TEAN O, Bras Da Silva C, Vega Toro P, Barre P, et al
    [Epidemiology of prostate cancer (PCa) in French Guyana (FG) - Preliminary results].
    Prog Urol. 2020 May 31. pii: S1166-7087(20)30167.
    PubMed     Abstract available

  12. LE PAIH JP, Bladou F, Klein C, Rouget B, et al
    [Predictive factors of active surveillance interruption for prostate cancer after 5years of follow-up].
    Prog Urol. 2020 May 29. pii: S1166-7087(20)30135.
    PubMed     Abstract available

    April 2020
  13. MORERE JF, Touboul C, Lhomel C, Roupret M, et al
    [Prostate cancer screening in France: Results from the EDIFICE surveys].
    Prog Urol. 2020 Apr 21. pii: S1166-7087(20)30096.
    PubMed     Abstract available

    March 2020
  14. VILLERS A, Bessaoud F, Tretarre B, Grosclaude P, et al
    Contamination in control group led to no effect of PSA-based screening on prostate cancer mortality at 9 years follow-up: Results of the French section of European Randomized Study of Screening for Prostate Cancer (ERSPC).
    Prog Urol. 2020 Mar 17. pii: S1166-7087(20)30056.
    PubMed     Abstract available

    [Prostate cancer].
    Prog Urol. 2020;30.

  16. SEFIK E, Eker A, Gunlusoy B, Celik S, et al
    The effect of alpha blocker treatment prior to prostate biopsy on voiding functions, pain scores and health-related quality-of-life outcomes: A prospective randomized trial.
    Prog Urol. 2020;30:198-204.
    PubMed     Abstract available

    February 2020
  17. PLANTE G, Bories PN, Denjean L, Pigat N, et al
    [TMPRSS2-Erg/AR-V7: Prognostic value of tests in urine and biopsy rince material in prostate cancer].
    Prog Urol. 2020 Feb 29. pii: S1166-7087(20)30028.
    PubMed     Abstract available

    December 2019
  18. GAULLIER M, Tricard T, Garnon J, Cazzato RL, et al
    [Percutaneous MR-guided prostate cancer cryoablation: Predictive factors and oncologic outcomes].
    Prog Urol. 2019 Dec 11. pii: S1166-7087(19)30605.
    PubMed     Abstract available

  19. BARDET F, Frontczak A, Schneider A, Delattre B, et al
    [Prostate MRI and screening: Practice survey with general practitioner of the "Bourgogne-Franche Comte" region].
    Prog Urol. 2019;29:974-980.
    PubMed     Abstract available

  20. DUQUESNE I, Champy C, Klap J, Chahwan C, et al
    [When to introduce hormone therapy after total prostatectomy with positive lymph nodes? Study of the factors influencing the time of introduction of hormone therapy].
    Prog Urol. 2019;29:981-988.
    PubMed     Abstract available

    November 2019
  21. TANGUY-MELAC A, Lesuffleur T, Fagot-Campagna A, Gastaldi-Menager C, et al
    Health care utilization by men with prostate cancer during the year before their death: A 2015 population-based study.
    Prog Urol. 2019 Nov 7. pii: S1166-7087(19)30540.
    PubMed     Abstract available

  22. MONGIAT-ARTUS P, Paillaud E, Caillet P, Albrand G, et al
    [Geriatric specificities of prostate cancer].
    Prog Urol. 2019;29:828-839.
    PubMed     Abstract available

    October 2019
  23. BASTIE JP, Game X, Roumiguie M
    [Key points of the announcement for metastatic prostate cancer].
    Prog Urol. 2019 Oct 20. pii: S1166-7087(19)30544.
    PubMed     Abstract available

  24. VENI T, Leroy V, Pradere B, Rebillard A, et al
    [Patients with prostate cancer treated by androgen deprivation therapy: Impact of adapted physical activity].
    Prog Urol. 2019 Oct 18. pii: S1166-7087(19)30539.
    PubMed     Abstract available

  25. THOMAS L, Lacarriere E, Martinache G, Martinache PR, et al
    [Experience of day case robotic prostatectomy. About thirty-two patients].
    Prog Urol. 2019;29:619-626.
    PubMed     Abstract available

    August 2019
  26. AOUN F, Albisinni S, Biaou I, Peltier A, et al
    Salvage Hemiablation High Intensity Focused Ultrasound for unilateral radio-recurrent prostate cancer.
    Prog Urol. 2019 Aug 7. pii: S1166-7087(19)30155.
    PubMed     Abstract available

    July 2019
  27. VALLAT A, Pillot P, Lebacle C, Irani J, et al
    [Prognostic value of testosterone during androgene deprivation therapy].
    Prog Urol. 2019 Jul 13. pii: S1166-7087(19)30153.
    PubMed     Abstract available

    The "Mini-Jupette" sling at the time of inflatable penile prosthesis implantation: Adequate treatment for erectile dysfunction with mild incontinence and/or climacturia after radical prostatectomy.
    Prog Urol. 2019 Jul 9. pii: S1166-7087(19)30112.
    PubMed     Abstract available

  29. ROSE DITE MODESTINE J, Neuzillet Y, Herve JM, Bosset PO, et al
    [12-year history of radical surgery indications for the treatment of prostate cancer].
    Prog Urol. 2019 Jul 4. pii: S1166-7087(19)30157.
    PubMed     Abstract available

    June 2019
  30. KLEINCLAUSS F, Frontczak A, Balssa L, Lebdai S, et al
    [Vascular targeted photodynamic therapy in low-risk prostate cancer. A literature review].
    Prog Urol. 2019 Jun 29. pii: S1166-7087(19)30113.
    PubMed     Abstract available

    [Toxicity of multimodal regimens in prostate cancer].
    Prog Urol. 2019;29 Suppl 1:S35-S41.
    PubMed     Abstract available

  32. KLEINCLAUSS F, Thiery-VuiUemin A
    [Oligometastatic prostate cancer management].
    Prog Urol. 2019;29 Suppl 1:S20-S34.
    PubMed     Abstract available

  33. ERRA B, Pradere B
    [Nuclear medicine for prostate cancer management].
    Prog Urol. 2019;29 Suppl 1:S2-S7.
    PubMed     Abstract available

    [Optimizing local control of high-risk prostate cancers through multimodal treatments].
    Prog Urol. 2019;29 Suppl 1:S8-S19.
    PubMed     Abstract available

  35. HOUEDE N
    [Management of patients with systemic treatments].
    Prog Urol. 2019;29 Suppl 1:S42-S50.
    PubMed     Abstract available


    Prog Urol. 2019;29 Suppl 1:S1.

    January 2019
  37. DELPORTE G, Olivier J, Ruffion A, Crouzet S, et al
    [Evolution of the number of incident cases, stage and first treatments for prostate cancer in France between 2001 and 2016].
    Prog Urol. 2019 Jan 8. pii: S1166-7087(18)30684.
    PubMed     Abstract available

    December 2018
  38. MOUREAUX C, Boucaud-Maitre D, Brureau L, Gourtaud G, et al
    [Pelvimetrics measures as predictives factors of positives surgical margins after robot-assisted laparoscopic prostatectomy].
    Prog Urol. 2018;28:906-914.
    PubMed     Abstract available

  39. THEVENIAUD PE, Zafar N, Hajj AE, Germain A, et al
    Mid term functional results following surgical treatment of recto-urinary fistulas postprostate cancer treatment.
    Prog Urol. 2018;28:915-920.
    PubMed     Abstract available

    November 2018
  40. ROZET F, Hennequin C, Beauval JB, Beuzeboc P, et al
    [French ccAFU guidelines - Update 2018-2020: Prostate cancer].
    Prog Urol. 2018 Nov 1. pii: S1166-7087(18)30514.
    PubMed     Abstract available

    October 2018
  41. PATARD PM, Roumiguie M, Prudhomme T, Doumerc N, et al
    Migration in last decade to high-risk prostate cancer after radical prostatectomy.
    Prog Urol. 2018 Oct 15. pii: S1166-7087(18)30557.
    PubMed     Abstract available

  42. ARNOUIL N, Gelet A, Matillon X, Rouviere O, et al
    [Focal HIFU vs robot-assisted total prostatectomy: Functionnal and oncologic outcomes at one year].
    Prog Urol. 2018;28:603-610.
    PubMed     Abstract available

    September 2018
  43. DELPORTE G, Henon F, Ploussard G, Briganti A, et al
    Radical prostatectomy for locally advanced and high-risk prostate cancer: A systematic review of the literature.
    Prog Urol. 2018 Sep 24. pii: S1166-7087(18)30472.
    PubMed     Abstract available

  44. AOUN F, Slaoui A, Walid EHO, Albisinni S, et al
    Association between phosphodiesterase type 5 inhibitors and prostate cancer: A systematic review.
    Prog Urol. 2018 Sep 7. pii: S1166-7087(18)30182.
    PubMed     Abstract available

  45. MEUNIER ME, Neuzillet Y, Radulescu C, Cherbonnier C, et al
    [Does the delay from prostate biopsy to radical prostatectomy influence the risk of biochemical recurrence?]
    Prog Urol. 2018;28:475-481.
    PubMed     Abstract available

    June 2018
  46. GURY L, Robert G, Bensadoun H
    [Where do we stand with benign prostatic hyperplasia day-case surgery: A laser effect?]
    Prog Urol. 2018 Jun 12. pii: S1166-7087(18)30121.
    PubMed     Abstract available

  47. BRUREAU L, Emeville E, Multigner L, Blanchet P, et al
    Predictors of biochemical recurrence after radical prostatectomy in an Afro-Caribbean population in Guadeloupe (French West Indies).
    Prog Urol. 2018;28.
    PubMed     Abstract available

  48. ALBISINNI S, Grosman J, Aoun F, Quackels T, et al
    Exploring positive surgical margins after minimally invasive radical prostatectomy: Does body habitus really make a difference ?
    Prog Urol. 2018;28.
    PubMed     Abstract available

    May 2018
  49. RAICHI A, Marcq G, Fantoni JC, Puech P, et al
    [Active surveillance in prostate cancer: Assessment of MRI in the selection and follow-up of patients].
    Prog Urol. 2018 May 31. pii: S1166-7087(18)30085.
    PubMed     Abstract available

  50. HACHI K, Boualga K, Chettibi K, Harouni M, et al
    [Study of the beneficial effects of triptorelin on lower urinary tract symptoms in Algeria in patients with non-localized prostate cancer].
    Prog Urol. 2018 May 20. pii: S1166-7087(18)30094.
    PubMed     Abstract available

  51. MARTIN-MALBURET A, Marcq G, Leroy X, Guiffart P, et al
    [Pathology findings after radical prostatectomy for prostate cancer in patients eligible for active surveillance: Contribution of multiparametric MRI to treatment decision].
    Prog Urol. 2018 May 20. pii: S1166-7087(18)30092.
    PubMed     Abstract available

    April 2018
  52. ROZET F, Hennequin C, Mongiat-Artus P, Beuzeboc P, et al
    [French CCAFU guidelines on prostate cancer: hormono-naive metastatic prostate cancer - update 2017].
    Prog Urol. 2018 Apr 18. pii: S1166-7087(18)30080.

    March 2018
  53. GEVORGYAN A, Hetet JF, Robert M, Duchattelle-Dussaule V, et al
    [Salvage cryotherapy of prostate cancer after failed external radiotherapy and brachytherapy: Morbidity and mid-term oncological results].
    Prog Urol. 2018 Mar 15. pii: S1166-7087(17)30543.
    PubMed     Abstract available

    February 2018
  54. SARRADIN M, Lepiney C, Celhay O, Delpech PO, et al
    [Estimating minimum period of time to perform prostate MRI after prostate biopsy: Clinical and histological bleeding risk factors; from a prospective study].
    Prog Urol. 2018;28:85-93.
    PubMed     Abstract available

    January 2018
  55. ALBISINNI S, Aoun F, Noel A, El Rassy E, et al
    Are concurrent systematic cores needed at the time of targeted biopsy in patients with prior negative prostate biopsies?
    Prog Urol. 2018;28:18-24.
    PubMed     Abstract available

    December 2017
  56. DE LA TAILLE A, Mardoyan S, Lafaye A
    [Psychological impact of prostate cancer on patients receiving a 6-month androgen deprivation therapy].
    Prog Urol. 2017 Dec 6. pii: S1166-7087(17)30625.
    PubMed     Abstract available

  57. DE VERGIE S, Gaschignard N, Baron M, Branchereau J, et al
    [Long-term outcomes of prostate cancer patients with lymph nodes metastasis after radical prostatectomy and pelvic lymph node dissection].
    Prog Urol. 2017 Dec 5. pii: S1166-7087(17)30624.
    PubMed     Abstract available

    November 2017
  58. DEFONTAINES J, Salomon L, Champy C, Cholley I, et al
    [Prostate cancer diagnostic by saturation randomized biopsy versus rigid targeted biopsy].
    Prog Urol. 2017 Nov 6. pii: S1166-7087(17)30536.
    PubMed     Abstract available

    September 2017
  59. RENARD-PENNA R, Sanchez-Salas R, Barret E, Cosset JM, et al
    [Evaluation and results of ablative therapies in prostate cancer].
    Prog Urol. 2017 Sep 19. pii: S1166-7087(17)30455.
    PubMed     Abstract available

  60. BARRET E, Sanchez-Salas R, Galiano M, Cathala N, et al
    [Management of ablative therapies in prostate cancer].
    Prog Urol. 2017 Sep 14. pii: S1166-7087(17)30411.
    PubMed     Abstract available

  61. SANCHEZ-SALAS R, Barret E, Renard-Penna R, Cosset JM, et al
    [Indications and limits of ablative therapies in prostate cancer].
    Prog Urol. 2017 Sep 14. pii: S1166-7087(17)30456.
    PubMed     Abstract available

    June 2017
  62. MARIEN A, De Castro Abreu A, Gill I, Villers A, et al
    [Interest using 3D ultrasound and MRI fusion biopsy for prostate cancer detection].
    Prog Urol. 2017 Jun 16. pii: S1166-7087(17)30130.
    PubMed     Abstract available

    May 2017
  63. VIDMAR R, Marcq G, Flamand V, Fantoni JC, et al
    [Salvage radical prostatectomy for recurrent prostate cancer. Morbidity, oncological and functional results].
    Prog Urol. 2017 May 30. pii: S1166-7087(17)30108.
    PubMed     Abstract available

  64. GIRIER D, Chevrot A, Costa P, Thuret R, et al
    [Sexual consequences after treatment of prostate cancer: Inquiry among members of the Association Nationale des Malades du Cancer de la Prostate].
    Prog Urol. 2017 May 5. pii: S1166-7087(17)30075.
    PubMed     Abstract available

    April 2017
  65. MONDET F, Alimi JC, Boyer C
    [Cancer plans apply to surgical treatment of prostate cancer: A geographically isolated center balance].
    Prog Urol. 2017 Apr 6. pii: S1166-7087(17)30046.
    PubMed     Abstract available

  66. ROZET F, Roupret M, Hennequin C, Massard C, et al
    [Management of a progressing prostate cancer: results of a national study].
    Prog Urol. 2017 Apr 6. pii: S1166-7087(17)30022.
    PubMed     Abstract available

    March 2017
  67. LONG JA, Poinas G, Fiard G, Lepretre M, et al
    [Robot assisted radical prostatectomy: What are the evidences at the time of a specific funding?]
    Prog Urol. 2017;27:146-157.
    PubMed     Abstract available

  68. LIMANI K, Albisinni S, Aoun F, Le Dinh D, et al
    [Quality of life after robotic prostatectomy: Impact of BMI and age on urinary incontinence].
    Prog Urol. 2017;27:244-252.
    PubMed     Abstract available

    November 2016
  69. COHEN J, Andre C, Mozer P
    [Targeted MRI prostate biopsies].
    Prog Urol. 2016;26:854-859.
    PubMed     Abstract available

    July 2016
  70. RIOUX-LECLERCQ N, Comperat E, Kammerer-Jacquet SF, Camparo P, et al
    [Pathological advances in renal, prostatic, bladder and testis neoplasia].
    Prog Urol. 2016 Jul 26. pii: S1166-7087(16)30070.
    PubMed     Abstract available

    May 2016
  71. BARRE C, Nguyen JM
    [Addendum concerning: "A prospective trial comparing consecutive series of open retropubic and robot-assisted laparoscopic radical prostatectomy in a centre: Oncologic and functional outcomes" written by J.B. Beauval et al. [Prog. Urol. 25 (2015) 370-
    Prog Urol. 2016;26:383-4.

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.